Endpoints News
FDA won't take enforcement action on Whoop Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
24 June, 2026
THE AVID EFFECT IS EXECUTION WITH PRECISION & PREDICTABILITY
Your Program. Delivered with Confidence.
sponsored by Avid Bioservices, Inc.
presented by HKSTP
The Next Decade of Biotech: Con­nect­ing the World via Cross-Bor­der Or­ches­tra­tors
spotlight
bioregnum
top stories
1. New FDA leadership strikes conciliatory note on rare diseases, staff morale
2. Whoop dodges FDA enforcement action
3. Former employee sues and claims BioNTech cut corners in pancreatic cancer trials
4. Ollin nets $330M to run Phase 3 trials of Vabysmo challenger from China
5. Lilly offers up to $1.9B in new drug discovery deal with Abbisko
more stories
• 
Lydia Ramsey Pflanzer
.

Don't miss tomorrow's virtual event at noon ET, where John Carroll will take you inside the most recent Endpoints 100 survey. The survey found that moods are improving compared to this time last year.
.
Lydia Ramsey Pflanzer
Deputy Editor, Endpoints News
From L-R: acting Chief of Staff Lowell Zeta, acting CBER chief Karim Mikhail, acting CDER director Michael Davis and BIO CEO John Crowley (courtesy BIO)
1
by Max Bayer

Af­ter a year of dis­rup­tions and in­dus­try con­ster­na­tion, a trio of cur­rent FDA lead­ers tried to turn over a new leaf both in the agency’s...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
2
by Shelby Livingston

The FDA said it will not take en­force­ment ac­tion against Whoop, near­ly a year af­ter it warned the wear­able mak­er over its blood pres­sure track­er...

Read the full story
3
by Zachary Brennan

A for­mer se­nior clin­i­cal tri­al man­ag­er at BioN­Tech sued the Ger­man com­pa­ny in North Car­oli­na dis­trict court on Mon­day, al­leg­ing pro­to­col de­vi­a­tions and oth­er safe­ty...

Read the full story
Jason Ehrlich, Ollin Biosciences CEO
4
by Lei Lei Wu

Ollin Bio­sciences an­nounced a $330 mil­lion Se­ries B to fund piv­otal stud­ies around what it hopes can be a more po­tent com­peti­tor to Genen­tech’s eye...

Read the full story
5
by Elizabeth Cairns

Build­ing on a pact from 2022, Eli Lil­ly has signed a new dis­cov­ery col­lab­o­ra­tion with Ab­bisko Ther­a­peu­tics that could see it pay the Chi­nese biotech...

Read the full story
Endpoints News